Revlimid® in the E.U. Multiple Myeloma Market
A Survey of 52 Hematology/Oncology Specialists
January 2009
Deliverable: Survey with key findings.
Study Description:
|
Topic |
Revlimid® in the E.U. Multiple Myeloma Market |
|
Respondent Type |
Physicians |
|
Specialties Covered |
Hematology/Oncology Specialists |
|
Region |
EU |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website Duration: Approximately 30 minutes’ duration Size: 52 total respondents Fielding Dates: Fielded online from December 22, 2008 to December 30, 2008 |
Objectives:
To understand current practices and trends regarding the use of newly approved agents in patients with multiple myeloma (MM) and the impact of newly approved Revlimid® in this market.
§ Determine current practice patterns in MM
§ Quantify usage of newly indicated agents in MM patients
§ Predict the barriers to entry of new therapies into a more price sensitive European market
§ Determine the effectiveness of Celgene’s commercial organization for launching Revlimid
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
Celgene Corporation |
CELG |
Revlimid® & Thalomid® |
|
Millennium |
MLNM |
Velcade® |
Inclusion Criteria and Respondent Demographics:
|
Inclusion Criteria |
§ European hematology/oncology specialists § At least 2 years in practice post-training § Spend at least 50% time in patient care § Manage at least 50 multiple myeloma patients § Have at most 75% of MM patients enrolled in clinical trials |
Print Abstract
For additional information on this study or to purchase, please call:
|
Survey
Oncology |